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ABSTRACT
Small interfering RNA (siRNA) molecules are potent
effectors of post-transcriptional gene silencing.
Using noninvasive bioluminescent imaging and a
mathematical model of siRNA delivery and function,
the effects of target-specific and treatment-specific
parameters on siRNA-mediated gene silencing are
monitored in cells stably expressing the firefly
luciferase protein. In vitro, luciferase protein levels
recover to pre-treatment values within ,1 week in
rapidly dividing cell lines, but take longer than
3 weeks to return to steady-state levels in nondividing
fibroblasts. Similar results are observed in vivo, with
knockdown lasting10 days in subcutaneous tumors
in A/J mice and 3–4 weeks in the nondividing
hepatocytes of BALB/c mice. These data indicate
that dilution due to cell division, and not intracellular
siRNA half-life, governs the duration of gene silencing
under these conditions. To demonstrate the practical
use of the model in treatment design, model calcula-
tions are used to predict the dosing schedule required
to maintain persistent silencing of target proteins with
different half-lives in rapidly dividing or nondividing
cells. The approach of bioluminescent imaging com-
bined with mathematical modeling provides useful
insights into siRNA function and may help expedite
the translation of siRNA into clinically relevant thera-
peutics for disease treatment and management.
INTRODUCTION
RNA interference (RNAi) refers to the ability of double-
stranded RNA (dsRNA) to cause sequence-specific degra-
dation of complementary mRNA molecules. Since its
discovery in Caenorhabditis elegans in 1998 (1), it has
rapidly attracted attention from researchers in fields ranging
from genetics to clinical medicine. A natural intracellular
process likely involved in cell-based defense against mobile
genetic elements such as viruses and transposons (2), RNAi
promises to be an invaluable tool for gene function analysis
as well as a powerful therapeutic agent that can be used
to silence pathogenic gene products associated with dis-
eases including cancer, viral infections and autoimmune
disorders (3–8).
A central component of RNAi is a double-stranded siRNA
molecule that is 21–23 nt in length with 2 nt long 30 overhangs
(9). These siRNA effector molecules can be introduced into
cells directly as synthetic siRNAs or indirectly as precursor
long dsRNAs or short-hairpin RNAs (shRNAs). RNA poly-
merase II- or III-driven expression cassettes can be used for
constitutive expression of shRNA molecules (10). Both the
long dsRNAs and shRNAs are cleaved by Dicer (RNase III
family of endonucleases) into the appropriately sized siRNA
effectors. Although the presence of dsRNA >30 nt can elicit an
interferon response in mammalian cells (11), Elbashir and co-
workers demonstrated that synthetic 21mer siRNAs evaded
the interferon response and yet were still effective mediators
of sequence-specific gene silencing in mammalian cells (9).
Here, we have chosen to focus on the use of synthetic 21mer
siRNA duplex molecules in mammalian cells for transient
gene silencing.
Because synthetic siRNA molecules must be transported
into the cells before they can function in RNAi, successful
delivery of siRNA is of central importance. Delivery vehicles
must protect the siRNA from nucleases in the serum or extra-
cellular media, enhance siRNA transport across the cell
membrane and guide the siRNA to its proper location through
interactions with the intracellular trafficking machinery.
While naked siRNA molecules have been shown to enter
cells, significantly more siRNA can be delivered using car-
rier vehicles (12,13). Both viral and nonviral vectors deli-
ver siRNA into cells, although viral vectors are limited to
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delivering siRNA-expressing constructs such as shRNA. Com-
mercially available cationic lipids such as Oligofectamine can
effectively deliver siRNA molecules into cells in vitro with
transfection efficiencies approaching 90% (9). However, the
high toxicity of cationic lipids limits their use for systemic
delivery in vivo. Recent studies from our laboratory have
shown that cyclodextrin-containing polycations (CDPs) can
achieve safe and effective systemic delivery of siRNA in
mice (14). Here, we consider the nonviral delivery of
siRNA using cationic lipids or polymers.
A challenge for the successful application of siRNA will
be to determine the dosing schedule required for efficacy,
making insights into the kinetics of siRNA-mediated gene
silencing foundational for the future clinical use of siRNA.
Without a proper understanding of the kinetics of the pro-
cess and the parameters that can affect the resulting gene
silencing, application of RNAi will be governed largely by
trial and error. The ability to specifically tailor and optimize
the treatment for each particular system would save significant
time and resources, especially given the high cost of synthetic
siRNA molecules and the amount of material required for
in vivo studies. Mathematical modeling using simple kinetic
equations for each step in the RNAi process can shed light
on many of these questions regarding the kinetic aspects of
RNAi. To our knowledge, there are only a few published
examples of such studies looking at the kinetics of the intra-
cellular RNAi process (15–18). Of these studies, none has
combined the delivery process and the interaction with the
RNAi machinery in mammalian cells. Bergstrom and
co-workers (15) proposed a unidirectional amplification
method in their mathematical model of RNAi-mediated
gene silencing. Because no RNA-dependent RNA polymerase
has yet been found in mammalian cells, they acknowledged
that their model did not address the silencing mechanisms
observed in mammals. Groenenboom and co-workers (16)
recently proposed a mathematical model for RNAi that
contained several extensions to the core RNAi pathway, pro-
viding for siRNA degradation by RNase as well as primed
amplification. Their model aimed to explain transgene-
or virus-induced gene silencing and avoidance of self-
reactivity, but did not consider any steps in the delivery
process. Similarly, Raab and Stephanopoulos (17) looked at
the dynamics of gene silencing by siRNA given at different
doses and at various times relative to plasmid transfection, but
did not incorporate siRNA delivery. Arciero and co-workers
(18) created a mathematical model to investigate tumor-
immune evasion and siRNA treatment. Although this model
provided insights into how siRNA can be used in cancer
treatment, it did not examine the delivery process and there
were no experimental data from in vitro or in vivo studies.
Here, we use bioluminescent imaging and mathematical
modeling to investigate the steps of RNAi from siRNA deliv-
ery to intracellular function with the aim of enabling the
practical application and design of siRNA-based treatment
strategies both in vitro and in vivo. Because the imaging is
noninvasive and nondestructive, the same set of cells or ani-
mals can be followed for the entire study. These results will
complement investigations using more traditional analytical
methods to monitor mRNA or protein knockdown and hope-
fully serve to encourage the rational design of experimental
and clinical siRNA-based treatments.
MATERIALS AND METHODS
Production of luciferase-expressing cell lines by
lentiviral transduction
Cell lines were incubated with viral supernatant containing
SMPU-R-MNCU3-LUC, a lentiviral vector based on HIV-1
that transduces the firefly luciferase gene. The backbone vector
SMPU-R has deletions of the enhancers and promoters of the
HIV-1 long terminal repeat (SIN), has minimal HIV-1 gag
sequences, contains the cPPT/CTS sequence from HIV-1,
has three copies of the UES polyadenylation enhancement
element from SV40 and has a minimal HIV-1 RRE [gift
from Paula Cannon, Children’s Hospital Los Angeles, Los
Angeles, CA (19)]. The vector has the U3 region from the
MND retroviral vector as an internal promoter driving expres-
sion of the firefly luciferase gene from SP-LUC+ [Promega,
Madison, WI (20)].
siRNA duplexes
All siRNA molecules were ordered purified and pre-annealed
(‘Option C’) from Dharmacon Research, Inc. (Lafayette, CO).
siGL3 (sense, 50-CUUACGCUGAGUACUUCGAdTdT-30;
antisense, 50-UCGAAGUACUCAGCGUAAGdTdT-30) is an
unmodified siRNA duplex that targets the luciferase gene,
while siCONTROL non-targeting siRNA #1 (siCON1; sense,
50-UAGCGACUAAACACAUCAAUU-30; antisense, 50-UUG-
AUGUGUUUAGUCGCUAUU-30) is an unmodified siRNA
duplex bioinformatically designed to minimize the potential
for targeting any known human or mouse genes.
In vitro transfections
Cells were seeded in 24-well plates 2–3 days prior to trans-
fection at 2 · 104–1 · 105 cells per well and grown in media
supplemented with 10% fetal bovine serum (FBS) and anti-
biotics (penicillin/streptomycin). siRNA was complexed
with Oligofectamine (Invitrogen, Carlsbad, CA) according
to the manufacturer’s instructions and applied to each well
in a total volume of 200 ml OptiMEM (Invitrogen). Trans-
fection medium was removed and replaced with complete
medium after 5 h.
Formation of subcutaneous tumors in mice
Luciferase-expressing Neuro2A (Neuro2A-Luc) cells were
grown to confluence in media supplemented with 10% FBS
and antibiotics (penicillin/streptomycin). Immediately prior to
injection, cells were washed with phosphate-buffered saline
(PBS), trypsinized and resuspended in serum-free media at
2 · 106 cells/ml. Each mouse received 0.5 ml of the resulting
cell suspension by subcutaneous injection.
Low-pressure tail-vein (LPTV) injection of
formulated siRNA polyplexes
All complexes were made with siRNA and an imidazole-
modified CDP (CDP-Im) synthesized as described previously
(21,22). Before addition to siRNA, CDP-Im was mixed with
an adamantane-PEG5000 (AD-PEG) conjugate and an AD-
PEG-transferrin (Tf) conjugate such that the total moles of
AD-PEG or AD-PEG-Tf equaled the number of moles of
b-CD. Tf-targeted polyplexes contained 1% AD-PEG-Tf rel-
ative to AD-PEG. This mixture was added to an equal volume
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of siRNA at a charge ratio (positive charges from CDP-Im to
negative charges from siRNA backbone) of 3:1 (+:). An
equal volume of 10% (w/v) glucose in water was added to
the resulting polyplexes to yield a 5% (w/v) glucose (D5W)
solution suitable for injection. Each mouse was injected with
200 ml of this polyplex solution containing 50 mg siRNA per
20 g mouse (2.5 mg/kg siRNA).
High-pressure tail-vein (HPTV) co-injection of
plasmid and siRNA
Hydrodynamic, or HPTV, injection of nucleic acids can
achieve significant levels of nucleic acid in the hepatocytes
of mice (23,24). A. McCaffrey and M. Kay kindly donated a
plasmid (pApoEHCRLuc) containing the firefly luciferase
gene under the control of the human a1-antitrypsin promoter
and the apolipoprotein E locus control region. For HPTV
co-injection studies in BALB/c mice, each 20 g mouse
received a 10% w/v injection of a D5W solution containing
0.25 mg/kg of the luciferase-containing plasmid and 2.5 mg/kg
siRNA.
Bioluminescent imaging
Cell culture plates or mice containing the luciferase-
expressing cells were imaged using the Xenogen IVIS 100
Imaging System (Xenogen, Alameda, CA). D-luciferin
(Xenogen) was dissolved in PBS at 15 g/l. For in vitro assays
in 24-well plates, 50 ml of the 15 g/l luciferin solution was
added to each well containing 1 ml of media. Light emission
was measured 2–3 min after addition of the luciferin. For
in vivo experiments, 0.2 ml of the 15 g/l luciferin solution
was injected intraperitoneally 10 min before measuring the
light emission. Mice were anesthetized with an initial dose
of 5% isoflurane followed by a maintenance dose of 2.5%
isoflurane. Bioluminescent signal intensities were quantified
using Living Image software (Xenogen).
Mathematical model
The model presented here was designed to allow the user
to specifically study the impact of parameter values on
gene silencing by RNAi. When designing an siRNA-based
treatment, the main controllable parameters are the
delivery method (naked siRNA, formulated with vector,
chemically modified) and dosing schedule. These choices
must be governed by parameters such as the target mRNA
half-life, target protein half-life, threshold for reduction
(in either target mRNA or protein), number of target cells
and desired knockdown duration. The model’s design
criteria therefore included the ability to enable user-defined
values for these parameters that characterize each experi-
mental system.
A simplified schematic of the major processes included in
the model is shown in Figure 1. Model variables (Table 1) and
parameters (Table 2) were used to develop a set of ordinary
differential equations for the steps involved in siRNA delivery
to and function within mammalian cells in vitro and in vivo.
The differential equations governing each major process from
the delivery of siRNA to its intracellular interaction with the
RNAi machinery are grouped into modules that can be
changed independently to modify the model complexity as
desired. A detailed description of the mathematical model
and the rationale for its design are provided in the Supple-
mentary Data.
Figure 1. Simplified schematic of the key steps required for siRNA delivery to and function within mammalian cells. Steps 1–3 are unique to in vivo application of
siRNA, whereas steps 4–9 represent the general processes on the level of an individual cell and are therefore common to both in vivo and in vitro application of siRNA.
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Circulation/extracellular transport
dBcf
dt
¼ kblooddis  Bcb  kbloodbind  Bcf
 ktransblood  partition  Bcf  kelimpl  Bcf
dBcb
dt
¼ kbloodbind  Bcf  kblooddis  Bcb
dEc
dt
¼ ktransblood  partition  Vp
Ve
 Bcf
 kint  Ec  Z  kelimec  Ec
:
Cellular uptake and intracellular trafficking
dEnc
dt
¼ kint  Ve
Vi
 Ec   kescendvec  Enc
 kunpackend  Enc  dilution  Enc
dEnna
dt
¼ kunpackend  Enc  kescendna  Enna
 kdegendna  Enna  dilution  Enna
dCc
dt
¼ kescendvec  Enc  kunpackcyt  Cc  dilution  Cc
dCna
dt
¼ kescendna  Enna þ kunpackcyt  Cc þ kdisRISC  R
 kf ormRISC  ðrtot  R  CÞ  Cna
 kdeginna  Cna  dilution  Cna
:
RNAi
dR
dt
¼ kf ormRISC  ðrtot  R  CÞ  Cna þ kdisRISCm  C
þ kcleavage  C  kdisRISC  R  kdegRISC  ðR þ CÞ
 kf ormRISCm  R  M  dilution  R
dC
dt
¼ kf ormRISCm  R  M  kdisRISCm  C
 kdegRISC  ðR þ CÞ  kcleavage  Cdilution  C
dM
dt
¼ kf ormmRNA þ kdisRISCm  C  kdegmRNA  M
 kf ormRISCm  R  M
:
Cell growth and target protein production
dP
dt
¼ kf ormprot  M  kdegprot  P
dZ
dt
¼ kgrowth  Z  1  Z
max
 
All of the equations for intracellular siRNA-associated species
contain a term to account for dilution due to cell division,
where dilution is equal to the ratio of new cells divided by
the total number of cells. For example, if the number of cells
doubles in 1 day, then dilution would equal 0.5 and the con-
centration of the intracellular species would likewise be
reduced by 50%. For the sake of calculation simplicity,
only species involving the delivered siRNA molecules are
diluted by this factor; all other intracellular species (i.e. target
mRNA and target protein) are assumed to not change after cell
division because they are produced intracellularly by both of
the daughter cells. The net effect of this is that the siRNA-
associated species are diluted equally between the two daugh-
ter cells after each cell division.
The set of ODEs was solved with MATLAB (The Math-
Works, Inc., Natick, MA) using the stiff ODE15s solver. The
ODE15s solver is a variable-order solver based on the numeri-
cal differentiation formulas. Parametric sensitivity analysis
was performed using SENS_SYS written by V. M. Garcia
Molla. This MATLAB routine is an extension to the
ODE15s solver that calculates the derivatives of the solution
with respect to the parameters.
RESULTS
In vitro and in vivo experiments were conducted to gain
insights into the general kinetics of siRNA-mediated gene
silencing in cell lines that constitutively express the luciferase
gene. Constitutively expressed genes, in contrast to genes
expressed transiently by plasmids, provide a more realistic
model for clinical application in which an endogenous
gene, such as an oncogene, is the target for a therapeutic
siRNA. The Xenogen IVIS 100 Imaging System allowed us
to monitor luciferase activity in luciferase-expressing cells
growing in 24-well plates or present in subcutaneous tumors
or livers in live mice; because the imaging was noninvasive,
luciferase activity was measured in the same plate of cells or
the same animals over the entire duration of the study. Moni-
toring the kinetics of siRNA-mediated gene silencing in the
same population of cells helps to avoid variability introduced
when using different cell populations for each time point as
required in luminometer-based luciferase detection or flow
cytometry (for fluorescent reporters). Additionally, firefly
luciferase has a short half-life of 2 h, so that its level should
change concomitantly with the level of mRNA (25,26). This
enables the use of bioluminescent imaging of luciferase pro-
tein activity as an indicator of mRNA transcript degradation by
the delivered siRNA molecules.
Effect of siRNA dose on luciferase knockdown in vitro
The amount of siRNA applied to the extracellular media has a
significant impact on the magnitude of the gene silencing but a
Table 1. Model variables
Name Model
compartment
Description (units)
Bcf Plasma Free complex in circulation (# vol1)
Bcb Plasma Bound complex in circulation (# vol1)
Ec Extracellular Extracellular complex in local vicinity (# vol1)
Enc Intracellular Endosomal complex (# vol1)
Enna Intracellular Endosomal free siRNA (# vol1)
Cc Intracellular Cytoplasmic complex (# vol1)
Cna Intracellular Cytoplasmic free siRNA (# vol1)
R Intracellular Activated RISC complex (# vol1)
C Intracellular Activated RISC complex bound to
mRNA (# vol1)
M Intracellular Target mRNA (# vol1)
P Intracellular Target protein (# vol1)
Z Intracellular Number of cells (#)
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minimal impact on the overall duration (Figure 2A). Using the
baseline parameters given in Table 2, the mathematical model
predicts the trends observed experimentally (Figure 2B).
Similar trends are observed with these siRNA doses in
other luciferase-expressing cell lines (data not shown).
Effect of cell doubling time on luciferase
knockdown in vitro
The majority of studies examining the kinetics of siRNA-
mediated gene silencing in vitro have used rapidly dividing
cell lines that typically have doubling times of 1 day. Using
these cell lines, the silencing effect generally lasts for 1 week
(27,28). To investigate whether this duration of silencing is
intrinsic to siRNA or a result of dilution due to cell division,
siRNA-mediated gene silencing was monitored in four
luciferase-expressing cell lines with different observed dou-
bling times: Neuro2A-Luc (0.8 days), LNCaP-Luc (1.4 days),
HeLa-Luc (1.6 days) and CCD-1074Sk-Luc (nondividing).
The cells were plated in 24-well plates and transfected
under identical conditions to enable direct observation of
the effect of cell doubling time alone. The experimental results
in Figure 3A reveal that the dilution effect from cell division
can alter the duration of gene silencing. Consistent with pre-
vious observations, the duration of gene silencing in rapidly
growing cell lines is 1 week; however, cell lines with slower
doubling times show a corresponding increase in the duration
of silencing. Figure 3B shows the predicted effect of cell
doubling time when the experimental transfection parameters
are input into the mathematical model. The model predictions
confirm that the dilution effect due to cell doubling time alone
can account for the decreased duration of gene silencing in
dividing cells. It is interesting to note that the duration of gene
silencing in nondividing cells is 3 weeks. This duration is
consistent with the kinetics observed in two previous reports
looking at siRNA-mediated gene silencing in nondividing
mammalian neurons and primary macrophages (29,30). In
nondividing cells, the duration of gene silencing is not con-
trolled by dilution from cell division but by the intrinsic sta-
bility of siRNA within the cell.
Kinetics of luciferase knockdown by
siRNA in subcutaneous tumors
Many tumors exhibit rapid growth with doubling times on the
order of only a few days, and the duration of gene silencing
Table 2. Model parameters
Name Description (units) Determination Value
max Maximum number of cells (#) Determined experimentally Fit to each system
partition Effective fraction of dose available to target cells Estimated from experimental data 1 · 103
rtot Total available amount of RISC protein complexes (# L1) Literature (42–44) 1.9 · 1015
Ve Extracellular volume (L) Specified experimentally in vitro,
Estimated from experimental
data and literature (45,46)
2 · 104
1 · 105
Vi Intracellular volume (L) Literature (47) 4 · 1012
Vp Plasma volume, mouse (L) Literature (48) 1.5 · 103
kbloodbind Complex binding to blood components (h1) Estimated from experimental data 1 · 104
kblooddis Complex dissociation from blood components (h1) Estimated from experimental data 1 · 102
kcleavage Cleavage of target mRNA by activated RISC complex (h1) Literature (44) 7.2
kdegendna Endosomal siRNA degradation (h1) Literature (32–34,49) 5 · 101
kdeginna Intracellular siRNA degradation (h1) Estimated from experimental
data and literature (33)
2.9 · 102
kdegmRNA Target mRNA degradation (h1) Literature (50–53) 2
kdegprot Target protein degradation, Luciferase (h1) Literature (25) 3.5 · 101
kdegRISC Activated RISC complex degradation (h1) Estimated from experimental data 7.7 · 102
kdisRISC Dissociation of activated RISC complex (h1) Chosen to be negligible once
activated RISC is formed
1 · 109
kdisRISCm Dissociation of activated RISC complex and target mRNA (h1) Literature (42–44) 1
kelimec Extracellular complex degradation (h1) Estimated from experimental data 8.7 · 102
2.9 · 102
kelimpl Plasma complex degradation (h1) Estimated from experimental data 5.8 · 102
kescendna Endosomal escape for siRNA (h1) Estimated from experimental
data and literature (54)
6 · 102
kescendvec Endosomal escape for complex (h1) Estimated from experimental
data and literature (54)
1 · 102
kformmRNA Formation of target mRNA (# L1 h1) Literature (50,51) 5.2 · 1013
kformprot Formation of target protein (h1) Literature (50,51) 5.2 · 102
kformRISC Formation of activated RISC complex (L #1 h1) Estimated from experimental data 2 · 1019
kformRISCm Formation of activated RISC/mRNA complex (L #1 h1) Literature (42–44) 1.1 · 1014
kgrowth Cell growth rate (h1) Determined experimentally Fit to each system
kint Internalization (h1) Literature (12,13,55) 1 · 105
5 · 107
ktransblood Transport from plasma to extracellular fluid (h1) Estimated from experimental data 1 · 102
kunpackcyt Cytosolic complex unpackaging (h1) Estimated from experimental data 5 · 101
6 · 102
kunpackend Endosomal complex unpackaging (h1) Estimated from experimental data 1 · 104
1 · 103
For parameters common to both in vitro and in vivo applications, the in vivo parameter values are shown in italics below the in vitro parameter values.
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should be limited by this rapid cell division. To test this
hypothesis, subcutaneous tumors were created in A/J mice
using luciferase-expressing Neuro2A-Luc cells. Since the
goal was to observe the kinetics of gene silencing and not
an actual therapeutic effect on the growth rate of the cells,
siRNA against the luciferase gene (siGL3) and a control
siRNA (siCON1) were used to show the sequence-
specificity of the luciferase knockdown. Each mouse received
three consecutive daily LPTV injections of transferrin-
targeted polyplexes containing 2.5 mg/kg siRNA. After quan-
tifying the luciferase activity in each tumor using the Xenogen
camera, data were used to create a predicted logistic growth
curve (Figure 4A). Because the siRNA targets only the
luciferase gene, the growth rate of the cells should be unaf-
fected; as a result, a decrease in luciferase signal intensity
indicates a change in the luciferase protein level. Normaliza-
tion to predicted growth curves allowed estimation of the
knockdown resulting from siRNA treatment (Figure 4B).
By adjusting only the parameters for the circulation/
extracellular transport of the siRNA polyplexes, very good
agreement was obtained between the model’s predictions
and the experimental data. The observed knockdown duration
after three consecutive injections was around 10 days, con-
sistent with the in vitro data for cell lines with similar observed
growth rates.
Kinetics of luciferase knockdown by
siRNA in hepatocytes
While cells in subcutaneous tumors are dividing rapidly (e.g.
once per day), most of the hepatocytes in a normal mouse liver
are in a state of growth arrest (31). Therefore, it was hypothe-
sized that gene silencing by siRNA would exhibit different
kinetics in hepatocytes versus tumors. Each BALB/c mouse
received a single HPTV injection of 0.25 mg/kg plasmid and
Figure 2. Effect of siRNA dose on the duration and magnitude of luciferase
knockdown by siRNA in nondividing cells. (A) Experimental results using
Oligofectamine to deliver siRNA to luciferase-expressing, nondividing fibro-
blasts with 1.5 · 105 cells per well in a 24-well plate. Data points represent the
ratio of the average luciferase signal intensity from triplicate wells receiving
siGL3 and siCON1 on day 0. Squares, 10 nM; diamonds, 25 nM; triangles,
50 nM; circles, 100 nM. (B) Luciferase knockdown after siRNA transfection
predicted by the mathematical model using the baseline in vitro parameters
given in Table 2 with the number of cells held constant at 1.5 · 105, a transfec-
tion time of 5 h, and a transfection efficiency of 90%.
Figure 3. Effect of cell doubling time on the duration of luciferase knockdown
by siRNA in vitro. (A) Experimental results using Oligofectamine to deliver
100 nM siRNA to luciferase-expressing cells with a range of doubling times
(dt). Data points represent the ratio of the average luciferase signal intensity
from triplicate wells receiving siGL3 and siCON1 on day 0. Squares, Neuro2A-
Luc (dt ¼ 0.8 d); diamonds, LNCaP-Luc (dt ¼ 1.4 d); triangles, HeLa-Luc
(dt ¼ 1.6 d); circles, CCD-1074Sk-Luc (nondividing). (B) Luciferase knock-
down after siRNA transfection predicted by the mathematical model using the
baseline in vitro parameters given in Table 2 with the initial number of dividing
and nondividing cells equal to 5 · 104 and 1.5 · 105, respectively, a transfec-
tion time of 5 h, and a transfection efficiency of 90%.
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2.5 mg/kg siGL3 on day 0, and the Xenogen camera was used
to follow the luciferase signal in each mouse liver. Normal-
ization to the signal intensity in mice that received plasmid
only (no siRNA) allowed quantification of the percent knock-
down by siRNA. Figure 5 shows the experimental data
together with the model predictions. Similar to the in vitro
results for gene silencing in nondividing cells, the duration of
gene silencing lasts for 3–4 weeks in the hepatocytes after a
single dose of siRNA.
Effect of siRNA stability on luciferase
knockdown by siRNA
Because both double-stranded and single-stranded nucleic
acids are rapidly degraded in serum, current efforts in the
field of nucleic acid-based therapeutics seek to enhance
the stability of the nucleic acids with the goal of increasing
the duration of gene silencing by boosting their bioavailability
and possibly prolonging their persistence intracellularly
(32–34). Layzer and co-workers studied the kinetics of gene
silencing in HeLa cells using 20-F-modified siRNA and
unmodified 20-OH siRNA. Although the 20-F-modified
siRNA led to a significant increase in serum stability, it
appeared to have no effect on the duration of gene silencing
after transfection. This suggests that the intracellular stability
of siRNA molecules is not the limiting factor controlling the
duration of gene silencing in rapidly dividing cells; instead,
dilution due to cell division limits how long gene silencing can
occur under these conditions. If the intracellular half-life of
siRNA molecules is already around 24 h, then even modifi-
cations to increase the half-life to >72 h have an insignificant
effect on the duration of gene silencing (Figure 6). These
model predictions corroborate the experimental results
obtained by Layzer and co-workers (33). On the other
hand, the outcome of using modified siRNA may be different
in slowly dividing or nondividing cells since the intracellular
siRNA half-life will be shorter than the cell doubling time,
meaning dilution due to cell division will no longer be the
dominant factor. Increasing the persistence of siRNA within
the cell might prolong the duration of gene silencing.
Results from such studies in nondividing cells should be inter-
preted carefully since the apparent intracellular stability of
Figure 4. Kinetics of luciferase knockdown by siRNA in Neuro2A-Luc sub-
cutaneous tumors in A/J mice. (A) Experimental and predicted results for
luciferase knockdown after three consecutive LPTV injections on days 6, 7
and 8 of transferrin-targeted CDP-Im polyplexes containing 50 mg siRNA per
20 g mouse. Experimental data points are shown for a mouse receiving siCON1
(squares) and a mouse receiving siGL3 (circles). Solid lines represent the
predicted luciferase signal with siRNA treatment and dashed lines represent
the predicted luciferase signal in the absence of siRNA treatment. (B) Normal-
ization of the observed luciferase signal in the siGL3-treated mouse to the
predicted luciferase signal in the absence of treatment. Circles indicate
the normalized experimental data points, while the solid line represents the
response predicted by the mathematical model using the baseline in vivo
parameters given in Table 2 and assuming that 50% of the total cells are reached
with each dose.
Figure 5. Kinetics of luciferase knockdown by siRNA in nondividing
hepatocytes in BALB/c mice. Experimental and predicted results are shown
for luciferase knockdown after hydrodynamic tail-vein co-injection of 5 mg
pApoEHCRLuc and 50mg siRNA per 20 g mouse on day 0. Circles represent the
ratio of the average luciferase signal intensity from three mice receiving
plasmid + siRNA to the luciferase signal intensity from three mice receiving
plasmid alone. The predicted luciferase knockdown, given by the solid line, was
calculated using the baseline in vivo parameters given in Table 2 with the
following modifications to account for hydrodynamic injection of naked siRNA
without a delivery vehicle: eliminate steps involving the complexes (kescend-
vec, kunpackend, kunpackcyt), modify uptake and intracellular trafficking to
match observed kinetics (partition ¼ 1 · 102, ktransblood ¼ 1, kint ¼ 1 ·
103 h1, kescendna ¼ 1 · 102 h1, kdegendna ¼ 5 · 103 h1), and
modify extracellular volume (Ve ¼ 1.5 · 105 L). The kescendna and
kdegendna may no longer represent endosomal processes as hydrodynamically
injected naked siRNA may be internalized through different vesicles or parti-
tioned into a separate intracellular compartment (e.g. nucleus) that exhibits
different degradation and release kinetics than in standard or receptor-mediated
endocytosis of siRNA-containing complexes. The total number of hepatocytes
was chosen to be 5 · 107, on the same order of magnitude as the number of
hepatocytes in a mouse liver (40,41).
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siRNA molecules may be caused by association with other
intracellular components or localization to specific compart-
ments, both of which could lead to degradation kinetics inde-
pendent of the properties of the siRNA molecules alone. In that
case, modified siRNA would not necessarily increase the dura-
tion of gene silencing relative to unmodified siRNA even in
nondividing cells.
Multiple doses to prolong luciferase knockdown by
siRNA in nondividing cells
The previous studies have looked at the transient knockdown
of the luciferase reporter gene by 1–3 injections of siRNA
over a short-term period; even in nondividing cells, the
maximum duration of silencing using typical siRNA doses
is 3–4 weeks. However, a clinically relevant treatment regi-
men using siRNA may require that a gene be silenced for a
prolonged period of time. Some have attempted to solve this
problem by using lentiviral delivery of expressed short-hairpin
siRNAs (shRNAs) to achieve sustained gene silencing in vitro
and in vivo (35,36). Precise control of the intracellular level of
siRNA and having a means to turn off its production when
treatment is no longer necessary represent two major chal-
lenges to this use of shRNA. On the other hand, the intrinsi-
cally transient nature of siRNAs makes them more amenable
to disease treatments in which the treatment is given over a
period of time and then stopped once the desired therapeutic
outcome (e.g. regression of a tumor or inhibition of viral
growth) is achieved. To illustrate how properly timed doses
of siRNA can prolong gene silencing by siRNA, nondividing
CCD-1074Sk-Luc cells were transfected with a second dose of
siRNA 4 days after the initial dose (Figure 7A). With a second
dose of 100 nM siRNA, the luciferase protein levels remained
at <40% of the steady-state value for an additional 4 days. If
the trends continue in such a fashion, a 100 nM dose every
4 days could lead to persistent gene silencing as shown by
model calculations in Figure 7B.
Considerations for siRNA-based treatments that
require a threshold knockdown for efficacy
Because siRNA treatment of rapidly dividing cells requires
treating more cells over time while also having to deal with
dilution effects, the amount of target gene or protein knock-
down will be less than that observed in slowly dividing or
nondividing cells. More frequent dosing is required to over-
come these barriers. Cancer is one example of a disease often
characterized by rapid cell division that may require target
gene knockdown lasting longer than that which can be
achieved with a single dose of siRNA. To address this situ-
ation, the mathematical model was used to estimate siRNA
dosing schedules needed to maintain a given gene below a
Figure 6. Effect of intracellular siRNA half-life on the duration of
siRNA-mediated gene silencing in vitro. Curves represent model predictions
for luciferase knockdown after transfection with 100 nM siRNA against
luciferase on day 0 with a cell doubling time of 1 day (kgrowth ¼ 0.0.029
h1) and intracellular siRNA half-lives of 24, 48 and 72 h (kdeginna ¼ 0.029,
0.014 and 0.01 h1). The initial number of cells was 5 · 104, transfection time
was 5 h, transfection efficiency was 90%, and all other parameters were kept
at their baseline in vitro values given in Table 2.
Figure 7. Effect of siRNA dose frequency on the duration of luciferase knock-
down by siRNA in nondividing cells. (A) Experimental results using
Oligofectamine to deliver siRNA to luciferase-expressing nondividing fibro-
blasts in vitro. Data points represent the ratio of the average luciferase signal
intensity from triplicate wells receiving siGL3 and siCON1. To facilitate com-
parison of the knockdown kinetics, the data points are normalized such that all
three curves exhibit the same magnitude of knockdown for the first four days
since all three received the same treatment over this period. This normalization
permits comparison of the kinetics of gene silencing observed with different
treatments even though the absolute magnitude of the knockdown varied
slightly in each experiment. Squares, 100 nM (day 0); diamonds, 100 nM
(day 0) + 10 nM (day 4); triangles, 100 nM (day 0) + 100 nM (day 4).
(B) Luciferase knockdown after siRNA transfection predicted by the
mathematical model using the baseline in vitro parameters given in Table 2
with the number of cells equal to 1.5 · 105, a transfection time of 5 h, and a
transfection efficiency of 90%.
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threshold value for an extended period of time in dividing
cells. While the magnitude of target gene (or protein) reduc-
tion or the duration of knockdown relative to the steady-state
value in the absence of treatment can be relatively good indi-
cators of the success of an siRNA treatment, the therapeutic
efficacy of an siRNA treatment regimen should perhaps be
judged by the length of time it is able to maintain the target
gene or protein level below a given threshold. Although a
short, substantial knockdown of certain targets may be suffi-
cient to trigger a cascade of downstream effects, other situa-
tions may require considerably longer knockdown to achieve
the desired therapeutic effect. Additionally, this therapeutic
effect may only be seen when the target protein is reduced
below a threshold, or some fraction of its pre-treatment value.
The data in Figure 8 show how the mathematical model can
be used to simulate the effects of cell doubling time and target
protein half-life during treatment with siRNA. To avoid
unnecessary complications, the calculations ignore the circu-
lation/extracellular transport and consider each siRNA dose
already in the local extracellular environment of the cells
(analogous to the in vitro situation). Figure 8A–D gives results
that demonstrate how target protein half-life can impact the
observed dynamics of protein knockdown with once- or twice-
weekly dosing in rapidly dividing or nondividing cells. For a
target protein with a short half-life in rapidly dividing cells,
even twice-weekly dosing still can result in significant oscil-
lations which may hinder the ability to cause a phenotypic
change in the target cells (Figure 8A). If the target protein has a
long half-life, then twice-weekly dosing is able to maintain
steady knockdown at 50% of the steady-state level, but this
magnitude of protein knockdown is not achieved until about a
week after the first dose of siRNA (Figure 8B). In nondividing
cells, once-weekly dosing is adequate to maintain persistent
silencing at 20% of the steady-state value (Figure 8C and D).
Again, this protein knockdown can only be achieved after
more than a week from the initial siRNA dose if the target
protein half-life is very long (Figure 8D). The fraction of the
total treatment time during which a target protein is below a
threshold (e.g. 50% steady-state value) can be used as a metric
to compare the efficacy of different treatment regimens. The
data illustrated in Figure 8E reveal how cell growth rate and
target protein half-life can affect protein knockdown when
siRNA is administered once on day 0, once-weekly or
twice-weekly over the 25-day treatment. As expected, cell
growth rate has a large impact on the duration of knockdown,
directly affecting the fraction of the total time that the target
protein level can be reduced below the threshold of 50%.
DISCUSSION
A more thorough understanding of the factors affecting the
kinetics of siRNA-mediated gene silencing should prove to be
invaluable for experimental and clinical applications of
siRNA. Given the relatively recent discovery of RNAi, details
of its action are still being elucidated, and many of the current
siRNA dosing schedules used in literature are based on prece-
dence rather than being optimized for each system. The high
cost of siRNA molecules, especially for in vivo studies, limits
systematic exploration of the parameter space needed to
achieve the most effective siRNA dosing schedule for each
model system. This situation can be partially rectified by
using mathematical modeling to give insights that help direct
experimental studies. Here, we employed bioluminescent
imaging and mathematical modeling to investigate the effects
of target-specific and treatment-specific parameters on siRNA-
mediated gene silencing in vitro and in vivo.
The experimental data presented here show the effects of
cell doubling time, siRNA dosing schedule, and siRNA deliv-
ery method on luciferase reporter-protein knockdown and aid
in developing mathematical models of siRNA delivery to and
function within mammalian cells. Luciferase knockdown in
cell lines engineered to constitutively express luciferase was
used to mimic the knockdown of an endogenously expressed
gene, analogous to an oncogene whose presence in a cell can
lead to tumorigenicity. The luciferase-expressing cell lines
were used in cell culture experiments or injected into mice
and then monitored for luciferase expression using noninva-
sive bioluminescent imaging with the Xenogen Imaging
System. The duration of gene silencing lasted for 1 week
in rapidly dividing cells but longer than 3 weeks in nondivid-
ing cells both in vitro and in vivo, supporting the hypothesis
that dilution due to cell division is the major factor controlling
the duration of luciferase knockdown in rapidly dividing cells.
The duration of gene silencing by siRNA can be longer than
that achieved with other nucleic acid-based gene inhibition
strategies, such as antisense, whose knockdown typically lasts
only on the order of 1–2 days. Bertrand and co-workers (37)
studied antisense- and siRNA-mediated inhibition of GFP in
HeLa cells and showed that while antisense-mediated inhibi-
tion diminished after only 1 day, the siRNA-mediated inhibi-
tion was still increasing. This significant difference in the
duration of gene silencing could become important when try-
ing to use either antisense or siRNA molecules as therapeutic
agents. In fact, the short duration of gene silencing by certain
nucleic acid-based gene inhibition strategies could preclude
their ability to alter cellular behavior if the target gene is not
silenced for an adequate amount of time. This would be par-
ticularly apparent if the target protein has a long intracellular
half-life; then, knockdown of the target mRNA may not result
in target protein knockdown if the mRNA levels can be res-
tored before a significant amount of protein has degraded.
The findings presented here highlight several key consid-
erations for experimental design when evaluating the efficacy
of siRNA against certain genes that produce proteins with long
half-lives. If the knockdown phenotype does not become
apparent until the protein is below a certain threshold, then
observation at early time points may not reveal any effect. This
is crucial for in vitro studies aimed at testing the ability of a
therapeutic siRNA to induce apoptosis or growth arrest in
certain cell lines. Common practice is to look at time points
within 48 and 72 h; here, model predictions suggest that these
time points may be too early if the target protein half-life is any
longer than a couple of days. Similar considerations should be
made when deciding dosing schedules for in vivo studies using
siRNA for protein knockdown in tumors (e.g. an oncogenic
fusion protein), since proteins with longer half-lives will show
a slower initial response to the therapy but will require less
frequent dosing for persistent silencing. An important area for
future research will be to determine to what extent a gene or
protein needs to be knocked down before the intended thera-
peutic effect is realized. Such information can be combined
with mathematical models like the one presented here to more
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Figure 8. Effect of cell doubling time and target protein half-life on the ability to maintain persistent gene silencing. All plots represent predicted mRNA (dashed
lines) and protein (solid lines) knockdown in transfected cells using the baseline in vitro parameters given in Table 2, a transfection time of 5 h, and an initial number
of dividing and nondividing cells equal to 5 · 104 and 1.5 · 105, respectively. (A) Dose of 100 nM siRNA every 3 days with a target protein half-life of
2 h (kdegprot ¼ 0.35 h1) in cells with a doubling time of 1 day (kgrowth ¼ 0.029 h1). (B) Dose of 100 nM siRNA every 3 days with a target protein
half-life of 48 h (kdegprot ¼ 0.014 h1) in cells with a doubling time of 1 day (kgrowth ¼ 0.029 h1). (C) Dose of 100 nM siRNA every 7 days with a target
protein half-life of 2 h (kdegprot ¼ 0.35 h1) in nondividing cells. (D) Dose of 100 nM siRNA every 7 days with a target protein half-life of 48 h (kdegprot ¼
0.014 h1) in nondividing cells. (E) Effect of variations in cell doubling time and target protein half-life on the ability to maintain a target protein level below a
threshold of 50% its pre-treatment value over the 25-day period. I, 100 nM (day 0); II, 100 nM (days 0, 7, 14); III, 100 nM (days 0, 3, 7, 10, 14, 17, 21, 24). Surface
vertices represent the fraction of the total time during which the relative protein level is below the 50% threshold.
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accurately determine the required treatment regimen needed to
achieve efficacy. Although the model in its current form does
not allow for treatment effects other than target gene knock-
down, the simple addition of a death parameter to the cell
growth equation could provide a target cell death rate that
depends on the reduction of the target protein level below a
certain threshold. Other slightly more complicated modifica-
tions to the current set of equations could incorporate recruit-
ment of immune effector cells, effects on angiogenesis or even
sensitization to other treatments including chemotherapy.
While the mathematical model can predict many of the
trends observed experimentally for the systems used here,
confidence in the actual magnitude and duration of the pre-
dicted gene silencing in hypothetical situations can still be
greatly increased as more accurate parameter values become
available. Parametric sensitivity analysis was performed using
the SENS_SYS modification of the ODE15s solver in MAT-
LAB. Parameters governing RISC formation (kformRISC) and
binding to target mRNA (kformRISCm) have a significant
impact on target mRNA or protein levels. Although studies
of the RISC complex are rapidly elucidating details of its
mechanism and kinetics, these parameters will need to be
refined as more data become available. Additional equations
will be needed to model a multi-step RISC formation process,
or the lumped rate constants currently used can be modified to
provide reasonable estimates of the overall kinetics. As
expected, target mRNA and protein levels are also sensitive
to parameters governing the siRNA delivery process, such as
cellular uptake, endosomal escape and vector unpackaging. It
will be important to determine these parameters for each indi-
vidual delivery vehicle since such rates will vary from system
to system. With knowledge of these different parameters, the
model can be used to mimic delivery by a variety of methods
including naked siRNA (by high-pressure or low-pressure tail-
vein injection) or formulation into liposomes, lipoplexes or
polyplexes. Such comparisons may reveal how the character-
istics of each delivery method specifically affect the kinetics of
gene silencing. This information may help to focus design
improvements for delivery vehicles or improve the efficacy
of treatment regimens employing them, as suggested in gen-
eral for gene delivery by Varga and co-workers (38). Of the
parameters intrinsic to the target cells, the most important are
the cell growth rate (dilution effect), compartment volumes
(that control the concentration of siRNA available to drive
uptake or association processes), and the stability of the target
mRNA and protein molecules. The current set of model equa-
tions predicts that the stability of the mRNA transcript has a
greater effect on the magnitude and duration of gene silencing
than the absolute transcript number. This is because the rel-
ative knockdown is controlled largely by the relative sizes of
the two mRNA degradation terms: natural turnover within the
cell and degradation by RNAi. Therefore, the contribution
from RNAi leads to greater deviation from the steady-state
mRNA level for more stable mRNA molecules. Similar rea-
soning can be applied to other gene inhibition strategies, such
as antisense, that act at the mRNA level (39).
Based on these findings and the literature to date, siRNA
appears to be the most potent and effective nucleic acid-based
therapeutic aimed at post-transcriptional gene silencing. The
siRNA molecules can achieve >80% target protein inhibition
at nanomolar concentrations, and their enhanced intracellular
stability enables knockdown that can last for weeks in nondi-
viding cells. It is shown here that an optimized siRNA-based
treatment schedule can be designed to achieve prolonged gene
silencing by properly timed injections of siRNA. Mathemati-
cal modeling can help to realize these optimized treatments at
a fraction of the time and cost that would be required by
experimentation alone. Although there is no substitute for
experimental data, especially for highly variable and not com-
pletely definable biological systems, model calculations can
help to guide effective experimental design and aid in data
interpretation. With the burgeoning interest in nucleic acid-
based therapeutics such as siRNA, development of mathemati-
cal models such as the one presented here may expedite their
translation into clinically relevant therapeutics for disease
treatment and management.
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